In view of the increasing incidence of bronchial asthma and the increasing percentage of patients resistant to conventional anti-inflammatory and bronchodilator therapy, research aimed at acquiring new knowledge regarding the pathogenesis of remodelling, the possibility of its influence, possibly delaying its onset, and the identification of new therapeutic goals that would expand the current treatment possibilities of the disease are considered highly relevant.Examination of the antiastmatic activity of new types of drugs that could be applied to the treatment and prevention of allergic asthma. From substances that could be used in the treatment of asthma, monitor the efficacy of: modulators of selected types of calcium, sodium, potassium, chloride and non-selective cation channels. Comprehensively evaluate their effectiveness on the sensitivity of respiratory defence mechanisms, degree of allergic inflammation, remodelling and activity of sensitised epithelium on an allergen-induced allergic inflammation model. In the case of selective PDE III, IV, V inhibitors, the aim of the project is to correlate pharmacodynamic activity with plasma drug levels, which will contribute to an increase in treatment efficiency and a possible reduction of the adverse effects of these drugs. As part of the prevention of allergic inflammation, evaluate the anti-asthmatic potential of natural substances with non-selective anti-inflammatory action: plant polyphenols (of the flavonol group) and plant polysaccharides. In the case of selective PDE III, IV, V inhibitors, the aim of the project is to correlate pharmacodynamic activity with plasma drug levels, which will contribute to an increase in treatment efficiency and a possible reduction of the adverse effects of these drugs.